Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety study of Xingxiao Pills in tumor and nodule patients
ChiCTR2300075712Phase 4Recruiting
- Sponsor
- Beijing University of Chinese Medicine East Hospital
- Start
- Sep 2023
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Xingxiao pill in Neoplasm, lung nodule (SPN), thyroid nodule and 3 more, sponsored by Beijing University of Chinese Medicine East Hospital. Primary endpoint: Adverse events. Started Sep 2023; status: recruiting.
02
Drugs
Xingxiao pill
03
Conditions
Neoplasmlung nodule (SPN)thyroid noduleAdenopathyFibromyoma (LM)
Beyond the preview
Go deeper on ChiCTR2300075712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075712.